These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32265875)

  • 1. Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
    Obasa AE; Mikasi SG; Brado D; Cloete R; Singh K; Neogi U; Jacobs GB
    Front Microbiol; 2020; 11():438. PubMed ID: 32265875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
    Obasa AE; Ambikan AT; Gupta S; Neogi U; Jacobs GB
    BMC Infect Dis; 2021 Feb; 21(1):214. PubMed ID: 33632139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.
    Parbie PK; Abana CZ; Kushitor D; Asigbee TW; Ntim NAA; Addo-Tetebo G; Ansong MRD; Ofori SB; Mizutani T; Runtuwene LR; Nishizawa M; Ishikawa K; Kiyono H; Ampofo WK; Matano T; Bonney EY; Kikuchi T
    Front Microbiol; 2022; 13():973771. PubMed ID: 36090108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.
    Sebastião CS; Abecasis AB; Jandondo D; Sebastião JMK; Vigário J; Comandante F; Pingarilho M; Pocongo B; Cassinela E; Gonçalves F; Gomes P; Giovanetti M; Francisco NM; Sacomboio E; Brito M; Neto de Vasconcelos J; Morais J; Pimentel V
    Sci Rep; 2024 Jul; 14(1):15893. PubMed ID: 38987263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
    Mikasi SG; Gichana JO; Van der Walt C; Brado D; Obasa AE; Njenda D; Messembe M; Lyonga E; Assoumou O; Cloete R; Ikomey GM; Jacobs GB
    AIDS Res Hum Retroviruses; 2020 May; 36(5):450-455. PubMed ID: 31830799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
    Deletsu SD; Maina EK; Quaye O; Ampofo WK; Awandare GA; Bonney EY
    Medicine (Baltimore); 2020 Feb; 99(7):e18777. PubMed ID: 32049783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
    Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
    Acharya A; Tagny CT; Mbanya D; Fonsah JY; Nchindap E; Kenmogne L; Jihyun M; Njamnshi AK; Kanmogne GD
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106437
    [No Abstract]   [Full Text] [Related]  

  • 10. Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China.
    Lai J; Liu Y; Han X; Huang A; Lin J; Ao W; Ye H; Chen Y
    Drug Des Devel Ther; 2021; 15():889-894. PubMed ID: 33679129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
    Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
    J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
    Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
    BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China.
    Zhang J; Sun B; Sheng Z; Ding X; Fan Q; Huang G; Guo Z; Zhong P; Liao L; Xing H; Xia Y; Chai C; Jiang J
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Resistance Mutations in a Population Before Antiretroviral Therapy Initiation in Northern South Africa.
    Ogola B; Matume ND; Mavhandu-Ramarumo LG; Tebit DM; Bessong PO
    AIDS Res Hum Retroviruses; 2022 Mar; 38(3):248-256. PubMed ID: 34107774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.
    Cheng CY; Tsai MS; Yang CJ; Cheng SH; Sun HY; Chang SF; Su LH; Su YC; Hung CC; Chang SY
    Infect Drug Resist; 2018; 11():849-859. PubMed ID: 29892199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
    Nzengui-Nzengui GF; Mourembou G; M'boyis-Kamdem H; Kombila-Koumavor AC; Ndjoyi-Mbiguino A
    BMC Infect Dis; 2024 Mar; 24(1):316. PubMed ID: 38486188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
    Chen GJ; Cheng CY; Yang CJ; Lee NY; Tang HJ; Huang SH; Huang MH; Liou BH; Lee YC; Lin CY; Hung TC; Lin SP; Sun HY; Chang SY; Hung CC;
    J Antimicrob Chemother; 2024 May; 79(5):1157-1163. PubMed ID: 38546761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.